Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.
By A. Cheng, C. Hsu, J. K. Lin, M. Hsu, Y. Ho, T. Shen, J. Ko, J. Lin, B. Lin, W. Ming-Shiang and 11 more. Anticancer Research, 2001
2,113 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/af019db3412681c7bf0c9df4dc636163fa744490
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Julie S. Jurenka
- Hongyu Zhou
- K. Harikumar
- S. Luca
- A. Goel
- Christopher S Beevers
- Ricky A. Sharma
- Shile Huang
Citations in the corpus
- Curcumin: the story so far. (2005, unknown): “5–8 g daily of curcumin for 3 months to patients with pre-invasive malignant or high risk pre-malignant conditions of the bladder, skin, cervix, stomach or oral mucosa [26].”
- Targets of curcumin (2011, methodology): “This finding is consistent with other data shown in preclinical models [255-257] and in humans [245,249,251,253].”
- “Spicing Up” of the Immune System by Curcumin (2007, background): “(10) and recent phase I clinical trials indicate that hu78 mans can tolerate a dose of curcumin as high as 12 g/day, 79 without any toxic side effects (11).”
- Curcumin: Preventive and Therapeutic Properties in Laboratory Studies and Clinical Trials (2008, unknown): “In another study of high-dose oral curcumin by Cheng and colleagues (47) in Taiwan, administration of up to 8 g daily of curcumin for 3 months to patients with preinvasive malignant or high-risk premalignant conditions had no adverse effects (47).”
- Bioactivity of dietary polyphenols: The role of metabolites (2020, background): “5–2 mM within one hour after administration (Cheng et al. 2001).”
- Curcumin as "Curecumin": from kitchen to clinic. (2008, background): “At least three different phase I clinical trials indicate that curcumin is well tolerated when taken at doses as high as 12 g/day [159,162] (Table 6).”
- Regulation of inflammation and redox signaling by dietary polyphenols. (2006, background): “Pharmacologically, curcumin has been found to be safe and human clinical trials indicated no dose-limiting toxicity when administered at doses up to 10 g/day [18].”